References
- Lindsay R, Hart DM, Aitken JM, MacDonald EB, Anderson JB, Clarke AC. Long-term prevention of postmenopausal osteoporosis by oestrogen. Evidence for an increased bone mass after delayed onset of oestrogen treatment. Lancet 1976;1:1038–41
- Torgerson DJ, Bell-Syer SE. Hormone replace-ment therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. J Am Med Assoc 2001;285:2891–7
- Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002;288:321–33
- Haarbo J, Hassager C, Jensen SB, Riis BJ, Christiansen C. Serum lipids, lipoproteins, and apolipoproteins during postmenopausal estrogen replacement therapy combined with either 19-nortestosterone derivatives or 17-hydroxy-progesterone derivatives. Am J Med 1991;90: 584–9
- Feeley KM, Wells M. Hormone replacement therapy and the endometrium. J Clin Pathol 2001;54:435–40
- Brooks SE, Yeatts-Peterson M, Baker SP, Reuter KL. Thickened endometrial stripe and/or endometrial fluid as a marker of pathology: fact or fancy? Gynecol Oncol 1996;63:19–24
- Leake R. Contents of HRT and mechanisms of action. J Epidemiol Biostat 1999;4:129–33
- Skouby SO. The rationale for a wider range of progestogens. Climacteric 2000;3(Suppl 2): 14–20
- Mansour D. Yasmin — a new oral contraceptive, a new progestogen: the reasons why. Eur J Contra cept Reprod Health Care 2000;5 (Suppl 3):9–16
- ICrattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000;62:29–38
- Fuhrmann U, Krattenmacher R, Slater EP, Fritzemeier KH. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and anti-androgenic potential. Contraception 1996;54: 243–51
- Lees B, Stevenson JC. The prevention of osteo-porosis using sequential low-dose hormone replacement therapy with estradiol-1713 and dydrogester one. Osteoporos Int 2001;12:251–8
- Stevenson JC, Teter P, Lees B. 1713-Estradiol (1 mg/day) continuously combined with dydro-gesterone (5, 10 or 20 mg/day) increases bone mineral density in postmenopausal women. Maturitas 2001;38: 197–203
- Alexandersen P, Byrjalsen I, Christiansen C. Piperazine oestrone sulphate and interrupted norethisterone in postmenopausal women: effects on bone mass, lipoprotein metabolism, climacteric symptoms, and adverse effects. Br J Obstet Gynaecol 2000;107:356–64
- Delmas PD, Confavreux E, Garnero P, et al. A combination of low doses of 1713-estradiol and norethisterone acetate prevents bone loss and normalizes bone turnover in postmenopausal women. Osteoporos Int 2000;11:177–87
- Arrenbrecht S, Boermans AJ. Effects of trans-dermal estradiol delivered by a matrix patch on bone density in hysterectomized, postmeno-pausal women: a 2-year placebo-controlled trial. Osteoporos Int 2002;13:176–83
- Marsh MS, Crook D, Whitcroft SI, Worthington M, Whitehead MI, Stevenson JC. Effect of con-tinuous combined estrogen and desogestrel hor-mone replacement therapy on serum lipids and lipoproteins. Obstet Gynecol 1994;83:19–23
- Ketola E, Sipila R, Makela M. Effectiveness of individual lifestyle interventions in reducing cardiovascular disease and risk factors. Ann Med 2000;32:239–51
- Hirvonen E, Malkonen M, Manninen V. Effects of different progestogens on lipoproteins during postmenopausal replacement therapy. N Engl J Med 1981;304:560–3
- Pickar JH, Bottiglioni F, Archer DF. Amenorrhea frequency with continuous combined hormone replacement therapy: a retrospective analysis. Menopause Study Group. Climacteric 1998;1: 130–6